Get started
Work

Abstract PS5-07-02: NRG-BR008: A phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer (HERO)

Year: 2026
Type: conference-abstract
DOI: 10.1158/1557-3265.sabcs25-ps5-07-02
Authors: M. P. Mitchell, L. Z. Braunstein, H. Bandos, W. M. Sikov, A. J. Khan, P. Y. Chen, P. A. Ganz, R. Jagsi, J. R. White, R. S. Cecchini, H. Kang, S. L. Puhalla, K. L. Bolton, E. P. Connolly, E. Stringer-Reasor, K. R. Gergelis, T. B. Julian, E. P. Mamounas, N. Wolmark
Institutions: The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, University of Pittsburgh, NRG Oncology, Brown University, Women & Infants Hospital of Rhode Island, Beaumont Hospital, Royal Oak, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, Emory University, Winship Cancer Institute, The University of Kansas Cancer Center, University of Kansas Medical Center, Loyola University Medical Center, Loyola University Chicago, Loyola Medicine, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Washington University in St. Louis, Columbia University Irving Medical Center, University of Alabama at Birmingham, O'Neal Comprehensive Cancer Center, University of Rochester Medicine, University of Rochester, Allegheny Health Network, AdventHealth Orlando, AdventHealth, NSABP Foundation
Language: English
Subfield: Cancer Research
Open Access status: closed
OpenAlex ID: W7129697937
Cites:
Cited by:
Related to: